Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens

Frontiers in Oncology

Oncology

Keiju Sasaki¹  Kota Ouchi¹  Sakura Taniguchi¹  Keigo Komine¹  Hiroo Imai¹  Hidekazu Shirota¹  Yoshifumi Kawamura¹  Yuki Kasahara¹  Chikashi Ishioka¹  Masanobu Takahashi¹  Yuya Yoshida¹  Ken Saijo¹ 

[1] Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan;Department of Clinical Oncology, Tohoku University Graduate school of Medicine, Sendai, Japan;

关键词: immune check point inhibitor;    pembrolizumab;    head and neck cancer;    depth of response;    predictive factor;   

DOI  :  10.3389/fonc.2023.1230731

 received in 2023-05-29, accepted in 2023-07-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundPembrolizumab-containing regimens are standards of care for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). The depth of response (DpR) predicts the survival of patients with several types of solid cancers; however, its association with the survival outcomes of patients with R/M HNSCC treated with pembrolizumab-containing regimens remains unclear.MethodsThis study included 66 patients with R/M HNSCC who received a pemblolizumab-containing regimen as a first-line therapy at Tohoku University Hospital, Sendai, Japan. The patients’ characteristics, combined positive score, baseline tumor size, tumor response, DpR, overall survival (OS), progression-free survival (PFS), PFS2, and adverse events were reviewed. The associations between DpR and survival outcomes were analyzed.ResultsThe 1 year-OS and 1 year-PFS rates of pembrolizumab-containing regimens were 69.4% and 24.4%, respectively. The response rate was 28.8%. The mean and median values of tumor change from baseline were 5.1% and −9.0%. In the correlation analysis, a significant negative correlation was observed between tumor change rate from baseline and survival outcomes (OS: r= −0.41, p=0.0017; PFS: r=−0.49, p<0.001). In the multivariate analysis, DpR with tumor change of ≤−45 was associated with better OS and PFS.ConclusionDpR induced by pembrolizumab-containing regimens may be a predictive factor for OS and PFS in patients with R/M HNSCC.

【 授权许可】

Unknown   
Copyright © 2023 Saijo, Imai, Ouchi, Sasaki, Yoshida, Kawamura, Taniguchi, Kasahara, Komine, Shirota, Takahashi and Ishioka